CareDx Inc (NASDAQ:CDNA) went up by 9.20% from its latest closing price compared to the recent 1-year high of $38.67. The company’s stock price has collected 34.16% of gains in the last five trading sessions. Press Release reported 14 hours ago that CareDx Receives Final Medicare Coverage Decision for AlloSure Heart
Is It Worth Investing in CareDx Inc (NASDAQ :CDNA) Right Now?
Plus, the 36-month beta value for CDNA is at 0.90. Opinions of the stock are interesting as 6 analysts out of 6 who provided ratings for CareDx Inc declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $44.50, which is $3.07 above the current price. CDNA currently public float of 48.03M and currently shorts hold a 11.67% ratio of that float. Today, the average trading volume of CDNA was 486.47K shares.
CDNA’s Market Performance
CDNA stocks went up by 34.16% for the week, with a monthly jump of 22.61% and a quarterly performance of 19.50%, while its annual performance rate touched 74.81%. The volatility ratio for the week stands at 7.53% while the volatility levels for the past 30 days are set at 6.06% for CareDx Inc. The simple moving average for the period of the last 20 days is 23.58% for CDNA stocks with a simple moving average of 48.29% for the last 200 days.
Analysts’ Opinion of CDNA
Many brokerage firms have already submitted their reports for CDNA stocks, with H.C. Wainwright repeating the rating for CDNA by listing it as a “Buy.” The predicted price for CDNA in the upcoming period, according to H.C. Wainwright is $40 based on the research report published on August 05th of the current year 2020.
BTIG Research, on the other hand, stated in their research note that they expect to see CDNA reach a price target of $40. The rating they have provided for CDNA stocks is “Buy” according to the report published on June 26th, 2020.
H.C. Wainwright gave a rating of “Buy” to CDNA, setting the target price at $37 in the report published on June 19th of the current year.
CDNA Trading at 23.82% from the 50-Day Moving Average
After a stumble in the market that brought CDNA to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 7.14% of gains for the given period.
Volatility was left at 6.06%, however, over the last 30 days, the volatility rate increased by 7.53%, as shares surge +20.68% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +20.12% upper at present.
During the last 5 trading sessions, CDNA rose by +34.16%, which changed the moving average for the period of 200-days by +84.46% in comparison to the 20-day moving average, which settled at $33.88. In addition, CareDx Inc saw 92.07% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at CDNA starting from Maag Peter, who sale 16,992 shares at the price of $37.59 back on Sep 30. After this action, Maag Peter now owns 421,974 shares of CareDx Inc, valued at $638,802 using the latest closing price.
Maag Peter, the Chief Executive Officer of CareDx Inc, sale 9,900 shares at $31.68 during a trade that took place back on Sep 08, which means that Maag Peter is holding 422,074 shares at $313,609 based on the most recent closing price.
Stock Fundamentals for CDNA
Current profitability levels for the company are sitting at:
- -18.83 for the present operating margin
- +63.20 for the gross margin
The net margin for CareDx Inc stands at -17.29. The total capital return value is set at -24.10, while invested capital returns managed to touch -22.50. Equity return is now at value -13.60, with -9.50 for asset returns.
Based on CareDx Inc (CDNA), the company’s capital structure generated 3.33 points at debt to equity in total, while total debt to capital is 3.22. Total debt to assets is 2.08, with long-term debt to equity ratio resting at 0.07. Finally, the long-term debt to capital ratio is 0.07.
When we switch over and look at the enterrpise to sales, we see a ratio of 6.88, with the company’s debt to enterprise value settled at 0.00. The receivables turnover for the company is 7.52 and the total asset turnover is 0.87. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.07.